

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 6, 2018

**Dextera Surgical Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-51772**  
(Commission  
File Number)

**94-3287832**  
(IRS Employer  
Identification No.)

**900 Saginaw Drive, Redwood City, CA**  
(Address of Principal Executive Offices)

**94063**  
(Zip Code)

Registrant's telephone number, including area code: (650) 364-9975

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As previously disclosed, on December 11, 2017, Dextera Surgical filed a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the "*Bankruptcy Court*"), and on February 20, 2018, Dextera Surgical sold substantially all of its assets to AesDex, LLC. As a result, Dextera Surgical has now ceased to operate as an operating company, and is in the process of winding down the company.

As a result of the current status of Dextera Surgical, and to assist in the wind-down of the company, the Board of Directors engaged Arch & Beam Global, LLC ("**A&BG**") to wind down the company, contingent upon and effective upon the approval of the Bankruptcy Court. In addition, the Board of Directors also took the following actions, contingent upon and effective on the approval of the Bankruptcy Court of the engagement of A&BG: (a) appointed Matthew English of A&BG as Dextera Surgical's Chief Restructuring Officer; and (b) terminated the employment of Robert Newell, Dextera Surgical's Chief Financial Officer.

On April 5, 2018, the Bankruptcy Court approved the engagement of A&BG and, accordingly, on that date: (a) Mr. English became Dextera Surgical's Chief Restructuring Officer, and in that capacity Dextera Surgical's principal executive officer, principal financial officer and principal accounting officer; and (b) Mr. Newell ceased to be an officer or employee of Dextera Surgical (including ceasing to be Dextera Surgical's principal executive officer, principal financial officer and principal accounting officer).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dextera Surgical Inc.

Date: April 6, 2018

/s/ Matthew English  
Matthew English  
Chief Restructuring Officer